ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

On location

Teclistamab Shows Promise for Myeloma in Phase I Trial

Approximately three-quarters of patients with relapsed and/or refractory multiple myeloma (MM) responded to treatment with the bispecific antibody teclistamab, according to results from a...
On location

CRISPR Gene Editing May Offer Curative Potential for Sickle Cell Disease

CRISPR-based gene editing techniques may offer curative potential for sickle cell disease (SCD) when used to target Krüppel-like factor 1 (KLF1) mutations, according to...
On location

Long-Term BELIEVE Analysis Finds Luspatercept Alleviates Transfusion Burden in Patients With Beta Thalassemia

A longitudinal analysis of data from the phase III BELIEVE trial showed that treatment with the activin receptor ligand trap luspatercept was associated with...
On location

Venetoclax and Azacitidine Combination Associated With Durable Responses in Higher-Risk MDS

More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented...
On location

Testing for Inherited Thrombophilias Provides Limited Benefit

Inherited thrombophilias are associated with an increased risk of initial and recurrent venous thromboembolism (VTE), but testing for these conditions in the setting of...
On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia

Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma

Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
On location

CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses

A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...
Advertisement

Current Issue

May 2021 Volume 7 Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Block title